Navigation Links
Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer

SAN FRANCISCO -- Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.

Findings from this Phase 2 Consortium (P2C) clinical trial were presented by the studys primary investigator, Keith Bible, M.D., Ph.D., at the Molecular Targets and Cancer Therapeutics International Conference, a jointly-sponsored symposium of the American Association for Cancer Research, National Cancer Institute and the European Organization for Research and Treatment of Cancer.

We are encouraged by the interim results of this trial, says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. Platinum-resistant ovarian cancer responds poorly to traditional therapies, and weve been working toward developing more effective treatments for this disease. This combination looks very promising.

More than 22,400 women in the United States will be diagnosed with ovarian cancer this year, according to the American Cancer Society, and nearly 15,300 women will die from it. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents).

In this study, the researchers evaluated a combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers. The researchers found in earlier preclinical studies that flavopiridol significantly boosts the anti-cancer effects of cisplatin, and later conducted a Phase I clinical trial to pilot the combination in patients (KC Bible et al, Clinical Cancer Research, 11:5935, 2005). The present Phase II trial was designed to extend this work and better determine this therapys effectiveness against platinum-resistant cancers.

Dr. Bible and his co-investigators treated 18 platinum-resistant Caucasian patients with this combination therapy. Of the 18 patients, all of whom were receiving the therapy as a second-line treatment after disease progression, one patient experienced complete response (all signs of cancer gone) and five other patients experienced partial responses (tumor regression). The 33 percent overall response rate (6 of 18 patients) is about twice as high as seen using traditional chemotherapy regimens.

The researchers also offered the combination therapy to five patients with platinum-sensitive (original therapy resulted in no recurrence for greater than 12 months) ovarian cancer. Of these women, one experienced complete response and three others partial response.

We now need to expand this trial to validate these interim results in additional patients, says Dr. Bible. Were also looking for ways to further boost the anti-cancer effects of the combination, in hopes of developing even more effective approaches to ovarian cancer.


Contact: Amy Tieder
Mayo Clinic

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. How do patients benefit of clinical trials
3. Magnetic resonance angiography in clinical medicine
4. Clinical trials need to be more frank
5. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
8. Clinical Comparisons Between ADHD Drugs Are Less
9. Specialized Clinics For Manipurs AIDS Patients
10. Outsourcing clinical trials to India
11. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, ... Today on September 18, 2015. The research, which was conducted at the Dental Institute ... and colleagues, show connections between stress during pregnancy and future dental health in the ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading Internet marketing ... launched "Publish Academy" training course . Singal's new program, in which he ... and marketers around the Internet are weighing in with reviews. , "Considering the ...
(Date:10/13/2015)... ... , ... Scientists in Seattle and Vancouver compared the diagnostic value of lung ... Surviving Mesothelioma has just posted an article on the new research. Click here ... the University of British Columbia found that certain genetic alterations were seen just as ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... School of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from the ... that has spanned four decades. , Dr. McLeod’s long and successful nursing practice ...
(Date:10/13/2015)... ... 13, 2015 , ... Breathing is one of the human ... According to T’ai Chi (also spelled “Taiji”) and Qigong Grand-masters Steven Aung, MD, ... with the 7,000 year old tradition they teach, can improve health, increase energy ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Oct. 13, 2015   Rosa & Co. LLC ... Quantitative Systems Pharmacology (QSP)/ PhysioPD™ , today announced that ... a workshop at the QSP Congress Meeting ... Boston, MA.  The conference focuses on the ...  Dr. Friedrich,s workshop is entitled "Using Mechanistic Physiological Models ...
(Date:10/13/2015)... , Oct. 13, 2015 China ... or " China Jo-Jo "), a leading China-based retail, ... products through its own online and retail pharmacies, announced ... Company,s official branded online pharmacy through , ... was a record 25%. China Jo-Jo,s ...
(Date:10/13/2015)... 13, 2015  Yesterday Congresswoman Renee Ellmers ... manufacturing site located in Holly Springs, NC ... produced Flucelvax ® (Influenza Vaccine) using cell-culture technology, a ... start-up and is not reliant on chicken eggs. 1,2 ... influenza vaccines business of Novartis AG in the US, ...
Breaking Medicine Technology: